Is SPPI stock a buy?
The consensus among 1 Wall Street analyst covering (NASDAQ: SPPI) stock is to Strong Buy SPPI stock.
Should I sell Spectrum Pharmaceuticals stock?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Spectrum Pharmaceuticals stock.
Did Sppi get FDA approval?
--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that its New Drug Application (NDA) for poziotinib has been accepted for review by the U.S. Food and Drug Administration (FDA).
Did Rolontis get approved?
The FDA turned down Rolontis' application to treat neutropenia in cancer patients on myelosuppressive therapies. In a complete response letter, the FDA raised issues with manufacturing “deficiencies” and flagged the need for a site reinspection, Spectrum said in a release.
Will Spectrum Pharmaceuticals go up?
The 5 analysts offering 12-month price forecasts for Spectrum Pharmaceuticals Inc have a median target of 4.00, with a high estimate of 10.00 and a low estimate of 3.00. The median estimate represents a +365.12% increase from the last price of 0.86.
When did Spectrum Pharmaceuticals go public?
Spectrum Pharmaceuticals Completes $42 Million Public Offering With Leading Biotech Institutional Investors. IRVINE, Calif., Sept 19, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Spectrum Pharmaceuticals, Inc.
Who owns SPPI stock?
Top 10 Owners of Spectrum Pharmaceuticals IncStockholderStakeShares ownedBlackRock Fund Advisors7.12%12,817,131D. E. Shaw & Co. LP4.36%7,845,726The Vanguard Group, Inc.4.25%7,646,403SSgA Funds Management, Inc.1.85%3,338,3166 more rows
Is Poziotinib FDA approved?
FDA Accepts New Drug Application for Poziotinib in HER2 Exon 20+ NSCLC. A new drug application has been accepted by the FDA for poziotinib in patients with advanced or metastatic non–small cell lung cancer with HER2 exon 20 insertion mutations.